Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1718-1722

  Schliemann, Christoph ^a   Wiedmer, Andrea ^a   Pedretti, Marta ^a   Szczepanowski, Monika ^b   Klapper, Wolfram ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Extra domain A of fibronectin; Extra domain A1 of tenascin C; Extra domain B of fibronectin; Lymphoma; Therapeutic antibodies; Vascular targeting

Indexed keywords

FIBRONECTIN; ISOPROTEIN; ONCOFETAL ANTIGEN; TENASCIN;

ANTIBODY DETECTION; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHADENITIS; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; PROTEIN ISOFORMS; TENASCIN;

EID: 70249129332     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.025     Document Type: Article

References (8)

1. Schliemann C., and Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 1776 (2007) 175-192
2. Pini A., Viti F., Santucci A., Carnemolla B., Zardi L., Neri P., et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273 (1998) 21769-21776
3. Villa A., Trachsel E., Kaspar M., Schliemann C., Sommavilla R., Rybak J.N., et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122 (2008) 2405-2413
4. Brack S.S., Silacci M., Birchler M., and Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12 (2006) 3200-3208
5. Schliemann C., Palumbo A., Zuberbuhler K., Villa A., Kaspar M., Trachsel E., et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113 (2009) 2275-2283
6. Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113 (2009) 2265-2274
7. Pedretti M., Soltermann A., Arni S., Weder W., Neri D., and Hillinger S. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 64 (2009) 28-33
8. Tijink B.M., Perk L.R., Budde M., Stigter-van Walsum M., Visser G.W., Kloet R.W., et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imag 36 (2009) 1235-1244